iBio 11/12/2024 Earnings Report

iBio EPS Results

• Actual EPS: -$0.46
• Consensus EPS: -$0.46
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

iBio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

iBio Announcement Details

• Date: 11/12/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

iBio (NYSE:IBIO) (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics. Through this platform, iBio offers contract development and manufacturing services (CDMO) to biopharmaceutical partners seeking flexible, modular production capacity. Its iBio Launch™ modular manufacturing units are engineered to accommodate everything from pilot-scale candidate evaluation to multi-metric commercial output, reducing the time and capital investment typically required for biologics production facilities.

In addition to its CDMO business model, iBio maintains an internal pipeline of vaccine candidates and therapeutic proteins. The company has engaged in collaborative research programs with academic institutions and government agencies to advance vaccine development against infectious diseases. These strategic alliances underscore iBio’s commitment to leveraging plant-based expression systems for rapid response to emerging health threats.

Founded in 1993 and headquartered in Bryan, Texas, iBio serves clients and partners across North America, Europe and Asia through its Texas-based facilities and global network of contract partners. Led by an experienced management team with deep roots in biopharmaceutical development, the company continues to expand its technological capabilities and manufacturing footprint to meet growing demand for next-generation biologics.